Download PDF
CC BY-NC-ND 4.0 · Indographics 2022; 01(02): 184-195
DOI: 10.1055/s-0042-1759556
Review Articles

Interventional Radiology in Hepatocellular Carcinoma: Current Status and Looking Ahead

Ashish Aravind
1   Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India
,
Amar Mukund 
1   Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and its incidence is on the rise. Although transplantation and surgical resection remain the definitive curative treatment options, only a minority of patients are eligible for these owing to advanced stage of disease at diagnosis. Over the last two decades, various interventional radiology (IR) therapies such as ablative and transarterial therapies, have come to the forefront of HCC management. IR also plays a role in preoperative management of HCC patients with procedures such as portal vein embolization. The recently updated Barcelona Clinic Liver Cancer (BCLC) staging system for HCC provides a guideline for choosing the optimum treatment modality for individual patients, with IR playing a central role. This review summarizes the different IR treatment options in HCC, including various ablative therapies, Transarterial Chemoembolization (TACE), Transarterial Radioembolization (TARE), Portal Vein embolization, emphasizing patient selection, procedural considerations and response evaluation.

Keywords

HCC - interventional radiological therapies - TACE - microwave ablation - radiofrequency ablation


Publication History

Article published online:
19 September 2023

© 2022. Indographics. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021; 73 (Suppl. 01) 4-13
    CrossrefPubMedSearch in Google Scholar
  • 2 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021
    PubMedSearch in Google Scholar
  • 3 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY Study. Hepatology 2021; 74 (05) 2342-2352
    CrossrefPubMedSearch in Google Scholar
  • 4 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol 2021; 44 (12) 1851-1867
    CrossrefPubMedSearch in Google Scholar
  • 5 Foltz G. Image-guided percutaneous ablation of hepatic malignancies. Semin Intervent Radiol 2014; 31 (02) 180-186
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998; 37 (03) 171-186
    CrossrefPubMedSearch in Google Scholar
  • 7 Ahmed M, Brace CL, Lee Jr FT, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011; 258 (02) 351-369
    CrossrefPubMedSearch in Google Scholar
  • 8 Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Roentgenol 2000; 174 (02) 323-331
    CrossrefPubMedSearch in Google Scholar
  • 9 Seidenfeld J, Korn A, Aronson N. Radiofrequency ablation of unresectable primary liver cancer. J Am Coll Surg 2002; 194 (06) 813-828 , discussion 828
    CrossrefPubMedSearch in Google Scholar
  • 10 Guglielmi A, Ruzzenente A, Sandri M. et al. Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg 2007; 11 (02) 143-149
    CrossrefPubMedSearch in Google Scholar
  • 11 Arch-Ferrer JE, Smith JK, Bynon S. et al. Radio-frequency ablation in cirrhotic patients with hepatocellular carcinoma. Am Surg 2003; 69 (12) 1067-1071
    CrossrefPubMedSearch in Google Scholar
  • 12 Lu DS, Raman SS, Limanond P. et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003; 14 (10) 1267-1274
    CrossrefPubMedSearch in Google Scholar
  • 13 Chang I, Mikityansky I, Wray-Cahen D, Pritchard WF, Karanian JW, Wood BJ. Effects of perfusion on radiofrequency ablation in swine kidneys. Radiology 2004; 231 (02) 500-505
    CrossrefPubMedSearch in Google Scholar
  • 14 Choi D, Lim HK, Kim MJ. et al. Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. AJR Am J Roentgenol 2005; 184 (06) 1860-1867
    CrossrefPubMedSearch in Google Scholar
  • 15 Akahane M, Koga H, Kato N. et al. Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 2005; 25 (Suppl. 01) S57-S68
    CrossrefPubMedSearch in Google Scholar
  • 16 Jaskolka JD, Asch MR, Kachura JR. et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol 2005; 16 (04) 485-491
    CrossrefPubMedSearch in Google Scholar
  • 17 Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl) S192-S203
    CrossrefPubMedSearch in Google Scholar
  • 18 Mala T. Cryoablation of liver tumours – a review of mechanisms, techniques and clinical outcome. Minim Invasive Ther Allied Technol 2006; 15 (01) 9-17
    CrossrefPubMedSearch in Google Scholar
  • 19 Littrup PJ, Ahmed A, Aoun HD. et al. CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol 2007; 18 (03) 383-392
    CrossrefPubMedSearch in Google Scholar
  • 20 Adam R, Hagopian EJ, Linhares M. et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002; 137 (12) 1332-1339 , discussion 1340
    CrossrefPubMedSearch in Google Scholar
  • 21 Narayanan G. Irreversible electroporation for treatment of liver cancer. Gastroenterol Hepatol (N Y) 2011; 7 (05) 313-316
    Search in Google Scholar
  • 22 Gadahadh R, Valenti D, Aljiffry M. et al. Surgery and interventional radiology collaborate on combination therapy in hepatocellular carcinoma. US Gastroenterol Hepatol Rev 2011; 7: 44-49
    Search in Google Scholar
  • 23 Ohnishi K. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatogastroenterology 1998; 45 (Suppl. 03) 1254-1258
    PubMedSearch in Google Scholar
  • 24 Virmani S, Ryu RK, Sato KT. et al. Effect of C-arm angiographic CT on transcatheter arterial chemoembolization of liver tumors. J Vasc Interv Radiol 2007; 18 (10) 1305-1309
    CrossrefPubMedSearch in Google Scholar
  • 25 Wallace MJ, Murthy R, Kamat PP. et al. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol 2007; 18 (12) 1500-1507
    CrossrefPubMedSearch in Google Scholar
  • 26 Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 2002; 224 (02) 542-547
    CrossrefPubMedSearch in Google Scholar
  • 27 Song SY, Chung JW, Lim HG, Park JH. Nonhepatic arteries originating from the hepatic arteries: angiographic analysis in 250 patients. J Vasc Interv Radiol 2006; 17 (03) 461-469
    CrossrefPubMedSearch in Google Scholar
  • 28 Kan Z, McCuskey PA, Wright KC, Wallace S. Role of Kupffer cells in iodized oil embolization. Invest Radiol 1994; 29 (11) 990-993
    CrossrefPubMedSearch in Google Scholar
  • 29 Chou FI, Fang KC, Chung C. et al. Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 1995; 22 (03) 379-386
    CrossrefPubMedSearch in Google Scholar
  • 30 Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990; 66 (09) 1897-1903
    CrossrefPubMedSearch in Google Scholar
  • 31 Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975; 36 (04) 1250-1257
    CrossrefPubMedSearch in Google Scholar
  • 32 Lammer J, Malagari K, Vogl T. et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (01) 41-52
    CrossrefPubMedSearch in Google Scholar
  • 33 Kulik LM, Atassi B, van Holsbeeck L. et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94 (07) 572-586
    CrossrefPubMedSearch in Google Scholar
  • 34 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009; 6 (03) 159-169
    CrossrefPubMedSearch in Google Scholar
  • 35 Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16 (03) 661-669
    CrossrefPubMedSearch in Google Scholar
  • 36 Cheng BQ, Jia CQ, Liu CT. et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 2008; 299 (14) 1669-1677
    CrossrefPubMedSearch in Google Scholar
  • 37 Kudo M, Ueshima K, Ikeda M. et al; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69 (08) 1492-1501
    CrossrefPubMedSearch in Google Scholar
  • 38 Marelli L, Stigliano R, Triantos C. et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006; 32 (08) 594-606
    CrossrefPubMedSearch in Google Scholar
  • 39 Schnapauff D, Tegel BR, Powerski MJ, Colletini F, Hamm B, Gebauer B. Interstitial brachytherapy in combination with previous transarterial embolization in patients with unresectable hepatocellular carcinoma. Anticancer Res 2019; 39 (03) 1329-1336
    CrossrefPubMedSearch in Google Scholar
  • 40 Manzano-Robleda MdelC, Barranco-Fragoso B, Uribe M, Méndez-Sánchez N. Portal vein thrombosis: what is new?. Ann Hepatol 2015; 14 (01) 20-27
    CrossrefPubMedSearch in Google Scholar
  • 41 Ikai I, Arii S, Okazaki M. et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007; 37 (09) 676-691
    CrossrefPubMedSearch in Google Scholar
  • 42 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 2013; 13: 60
    CrossrefPubMedSearch in Google Scholar
  • 43 Chao Y, Chung YH, Han G. et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer 2015; 136 (06) 1458-1467
    CrossrefPubMedSearch in Google Scholar
  • 44 Vilgrain V, Pereira H, Assenat E. et al; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (12) 1624-1636
    CrossrefPubMedSearch in Google Scholar
  • 45 Chow PHW, Gandhi M. Asia-Pacific Hepatocellular Carcinoma Trials Group. Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study. J Clin Oncol 2017; 35: 4002-4002
    CrossrefSearch in Google Scholar
  • 46 Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006; 141 (02) 191-198
    CrossrefPubMedSearch in Google Scholar
  • 47 American College of Radiology. Liver Imaging Reporting and Data System (LI-RADS) v2018 ACR.org: ACR. 2018 . Accessed Nov 3, 2022, at: https://www.acr.org/-/media/ACR/FILES/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en
    PubMedSearch in Google Scholar
  • 48 Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254 (01) 47-66
    CrossrefPubMedSearch in Google Scholar
  • 49 Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 2011; 260 (03) 752-761
    CrossrefPubMedSearch in Google Scholar
  • 50 Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009; 193 (04) 1044-1052
    CrossrefPubMedSearch in Google Scholar
  • 51 Woo S, Lee JM, Yoon JH, Joo I, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. Radiology 2014; 270 (03) 758-767
    CrossrefPubMedSearch in Google Scholar
  • 52 Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94 (11) 1386-1394
    CrossrefPubMedSearch in Google Scholar
  • 53 Chew V, Lee YH, Pan L. et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019; 68 (02) 335-346
    CrossrefPubMedSearch in Google Scholar
  • 54 Park W, Cho S, Ji J, Lewandowski RJ, Larson AC, Kim DH. Development and validation of sorafenib-eluting microspheres to enhance therapeutic efficacy of transcatheter arterial chemoembolization in a rat model of hepatocellular carcinoma. Radiol Imaging Cancer 2021; 3 (01) e200006
    CrossrefPubMedSearch in Google Scholar